Zydus Lifesciences Limited has marked a major milestone in India’s oncology landscape with the launch of Tishtha™, the world’s first biosimilar of Nivolumab. The launch reinforces Zydus’ growing strength in advanced biologics and Immuno-Oncology while significantly improving access to modern cancer treatment for patients in India.
Tishtha™ has been introduced in two strengths, 100 mg and 40 mg, priced at ₹28,950 and ₹13,950 respectively. These prices are approximately one-fourth of the reference drug, significantly reducing the overall cost of immunotherapy for patients. The dual-strength offering also allows clinicians to optimise dosing more precisely, helping minimise wastage and improve treatment economics, which is a key consideration in long-term cancer care.
Speaking on the launch, Dr. Sharvil P. Patel, Managing Director of Zydus Lifesciences Ltd., highlighted the company’s patient-centric approach. He stated that timely access to affordable and advanced cancer care remains central to Zydus’ vision, and that the launch of Tishtha™ is aimed at expanding access to Immuno-Oncology therapies while supporting patients consistently throughout their treatment journey.
Access to modern cancer treatment is largely determined by consistency, affordability, and reach. For patients who require checkpoint inhibitor therapy over multiple cycles, uninterrupted availability is critical, as treatment gaps can increase both clinical risks and financial stress. Developed and manufactured in India, Tishtha™ ensures dependable long-term supply, helping patients maintain continuity of care without uncertainty.
